Transgene (France) Performance
Transgene has a performance score of 3 on a scale of 0 to 100. The entity has a beta of -0.75, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Transgene are expected to decrease at a much lower rate. During the bear market, Transgene is likely to outperform the market. Transgene SA right now has a risk of 3.05%. Please validate Transgene coefficient of variation, maximum drawdown, skewness, as well as the relationship between the information ratio and downside variance , to decide if Transgene will be following its existing price patterns.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Transgene SA are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak technical and fundamental indicators, Transgene may actually be approaching a critical reversion point that can send shares even higher in July 2024. ...more
| Begin Period Cash Flow | 5.3 M | |
| Total Cashflows From Investing Activities | 16.8 M |
Transgene |
Transgene Relative Risk vs. Return Landscape
If you would invest 115.00 in Transgene SA on March 14, 2024 and sell it today you would earn a total of 8.00 from holding Transgene SA or generate 6.96% return on investment over 90 days. Transgene SA is generating 0.1549% of daily returns assuming 3.0523% volatility of returns over the 90 days investment horizon. Simply put, 27% of all stocks have less volatile historical return distribution than Transgene, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Transgene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Transgene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Transgene SA, and traders can use it to determine the average amount a Transgene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0508
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TNG | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.05 actual daily | 27 73% of assets are more volatile |
Expected Return
| 0.15 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Transgene is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Transgene by adding it to a well-diversified portfolio.
Transgene Fundamentals Growth
Transgene Stock prices reflect investors' perceptions of the future prospects and financial health of Transgene, and Transgene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Transgene Stock performance.
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.39) % | |||
| Current Valuation | 144.73 M | |||
| Shares Outstanding | 100.2 M | |||
| Price To Earning | 18.08 X | |||
| Price To Book | 3.39 X | |||
| Price To Sales | 10.07 X | |||
| Revenue | 9.99 M | |||
| EBITDA | (16.55 M) | |||
| Cash And Equivalents | 16.9 M | |||
| Cash Per Share | 0.27 X | |||
| Debt To Equity | 162.30 % | |||
| Book Value Per Share | 0.55 X | |||
| Cash Flow From Operations | (31.94 M) | |||
| Earnings Per Share | (0.23) X | |||
| Total Asset | 101.84 M | |||
| Retained Earnings | (538 M) | |||
| Current Asset | 51 M | |||
| Current Liabilities | 27 M | |||
About Transgene Performance
To evaluate Transgene SA Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Transgene generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Transgene Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Transgene SA market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Transgene's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. TRANSGENE operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 132 people.Things to note about Transgene SA performance evaluation
Checking the ongoing alerts about Transgene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Transgene SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Transgene SA is not yet fully synchronised with the market data | |
| Transgene SA may become a speculative penny stock | |
| Transgene SA had very high historical volatility over the last 90 days | |
| Transgene SA has a very high chance of going through financial distress in the upcoming years | |
| Transgene SA has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the revenue of 9.99 M. Net Loss for the year was (19.54 M) with loss before overhead, payroll, taxes, and interest of (15.87 M). | |
| Transgene SA has accumulated about 16.9 M in cash with (31.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27. |
- Analyzing Transgene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Transgene's stock is overvalued or undervalued compared to its peers.
- Examining Transgene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Transgene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Transgene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Transgene's stock. These opinions can provide insight into Transgene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Transgene Stock analysis
When running Transgene's price analysis, check to measure Transgene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transgene is operating at the current time. Most of Transgene's value examination focuses on studying past and present price action to predict the probability of Transgene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transgene's price. Additionally, you may evaluate how the addition of Transgene to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |